NO318070B1 - Substituerte, kondenserte heterosykliske forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene til fremstilling av medikamenter - Google Patents

Substituerte, kondenserte heterosykliske forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene til fremstilling av medikamenter Download PDF

Info

Publication number
NO318070B1
NO318070B1 NO20001816A NO20001816A NO318070B1 NO 318070 B1 NO318070 B1 NO 318070B1 NO 20001816 A NO20001816 A NO 20001816A NO 20001816 A NO20001816 A NO 20001816A NO 318070 B1 NO318070 B1 NO 318070B1
Authority
NO
Norway
Prior art keywords
group
substituted
methyl
benzyl
ylmethoxy
Prior art date
Application number
NO20001816A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001816D0 (no
NO20001816L (no
Inventor
Kunio Wada
Takashi Fujita
Toshihiko Fujiwara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20001816D0 publication Critical patent/NO20001816D0/no
Publication of NO20001816L publication Critical patent/NO20001816L/no
Publication of NO318070B1 publication Critical patent/NO318070B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Joining Of Building Structures In Genera (AREA)
NO20001816A 1997-10-08 2000-04-07 Substituerte, kondenserte heterosykliske forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene til fremstilling av medikamenter NO318070B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27606397 1997-10-08
PCT/JP1998/004548 WO1999018081A1 (fr) 1997-10-08 1998-10-08 Composes heterocycliques condenses substitues

Publications (3)

Publication Number Publication Date
NO20001816D0 NO20001816D0 (no) 2000-04-07
NO20001816L NO20001816L (no) 2000-06-07
NO318070B1 true NO318070B1 (no) 2005-01-31

Family

ID=17564291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001816A NO318070B1 (no) 1997-10-08 2000-04-07 Substituerte, kondenserte heterosykliske forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene til fremstilling av medikamenter

Country Status (25)

Country Link
US (1) US6432993B1 (cs)
EP (1) EP1022272B1 (cs)
KR (1) KR100666887B1 (cs)
CN (1) CN1255386C (cs)
AT (1) ATE267814T1 (cs)
AU (1) AU740704B2 (cs)
BR (1) BR9813848B1 (cs)
CA (1) CA2305807C (cs)
CZ (1) CZ302475B6 (cs)
DE (1) DE69824194T2 (cs)
DK (1) DK1022272T3 (cs)
ES (1) ES2221203T3 (cs)
HK (1) HK1027354A1 (cs)
HU (1) HU228193B1 (cs)
ID (1) ID23891A (cs)
IL (1) IL135537A (cs)
MX (1) MXPA00003546A (cs)
NO (1) NO318070B1 (cs)
NZ (1) NZ503794A (cs)
PL (1) PL200859B1 (cs)
PT (1) PT1022272E (cs)
RU (1) RU2196141C2 (cs)
TR (1) TR200000946T2 (cs)
TW (1) TW475931B (cs)
WO (1) WO1999018081A1 (cs)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW550264B (en) * 1999-04-07 2003-09-01 Sankyo Co Amine derivated compounds and the pharmaceutical compositions thereof
AU3670900A (en) * 1999-04-08 2000-11-14 Sankyo Company Limited Substituted fused imidazole derivatives
CA2377233C (en) 1999-06-28 2009-03-10 Sankyo Company, Limited Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof
JP2001072671A (ja) * 1999-06-28 2001-03-21 Sankyo Co Ltd ベンズイミダゾール化合物の合成中間体およびその製造方法
TR200200111T2 (tr) * 1999-07-19 2002-08-21 Sankyo Company Limited Neoplazmalar için terapötik ve profilaktik maddeler
FI20000542A (fi) * 2000-03-09 2001-09-10 Nokia Networks Oy Siirtokapasiteettien sovittaminen pakettivälitteisessä verkossa
WO2002013864A1 (fr) * 2000-08-16 2002-02-21 Sankyo Company, Limited Preparation medicinale de prevention et traitement du cancer
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2003033494A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Derive de benzimidazole
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
TW200300677A (en) * 2001-12-11 2003-06-16 Sankyo Co A pharmaceutical composition
TW200403055A (en) * 2002-06-25 2004-03-01 Sankyo Co Pharmaceutical composition of a peroxisome proliferator-activated receptor (PPAR) gamma atcivetor and a diuretic
AU2003254795A1 (en) * 2002-08-02 2004-02-23 Sankyo Company, Limited Resorcinol derivative
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7816552B2 (en) 2004-09-28 2010-10-19 Sankyo Company, Limited Intermediate of 6-substituted 1-methyl-1-H-benzimidazole derivative and method for producing same
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US20060106014A1 (en) * 2004-10-14 2006-05-18 Sekhar Boddupalli Methods for treating diabetes
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006086464A2 (en) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
TW200800181A (en) * 2006-02-09 2008-01-01 Sankyo Co Pharmaceutical composition for anticancer
TW200813039A (en) 2006-04-19 2008-03-16 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
CN102863362A (zh) * 2006-12-02 2013-01-09 财团法人首尔大学校产学协力财团 作为ppar配体的芳基化合物及其用途
TW201336497A (zh) * 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd 噻唑啶二酮化合物之結晶型及其製法
MX2009010790A (es) 2007-04-05 2009-10-29 Daiichi Sankyo Co Ltd Derivados de heteroarilo biciclico fusionados.
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
TW201008936A (en) 2008-07-31 2010-03-01 Daiichi Sankyo Co Ltd Crystalline forms of thiazolidinedione compound and its manufacturing method
EP2305673A4 (en) * 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
EA201101231A1 (ru) 2009-03-27 2012-06-29 Бристол-Майерс Сквибб Компани Способы предотвращения или снижения риска смертности
EP2505587A1 (en) * 2009-11-26 2012-10-03 Daiichi Sankyo Company, Limited Method for manufacturing a 6-substituted-1-methyl-1h-benzimidazole derivative, and manufacturing intermediate from said method
US8207351B2 (en) * 2010-04-30 2012-06-26 International Business Machines Corporation Cyclic carbonyl compounds with pendant carbonate groups, preparations thereof, and polymers therefrom
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9586900B2 (en) 2012-09-05 2017-03-07 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014121036A1 (en) * 2013-02-01 2014-08-07 Deuterx, Llc 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
AU2019304032B2 (en) 2018-07-19 2021-12-09 Astrazeneca Ab Methods of treating HFpEF employing dapagliflozin and compositions comprising the same
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
KR930701420A (ko) 1990-08-23 1993-06-11 알렌 제이. 스피겔 혈당저하제로서의 하이드록시우레아 유도체
GB9023584D0 (en) 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023585D0 (en) 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
RU2151145C1 (ru) 1994-04-11 2000-06-20 Санкио Компани Лимитед Промежуточное соединение для получения гетероциклических соединений, обладающих антидиабетической активностью
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
JP3291164B2 (ja) * 1995-06-02 2002-06-10 日石三菱株式会社 接触分解ガソリンの脱硫方法
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
IL120443A (en) 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
JPH1072371A (ja) * 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤

Also Published As

Publication number Publication date
KR100666887B1 (ko) 2007-01-10
DK1022272T3 (da) 2004-09-27
IL135537A (en) 2006-08-20
IL135537A0 (en) 2001-05-20
EP1022272B1 (en) 2004-05-26
NO20001816D0 (no) 2000-04-07
PL339771A1 (en) 2001-01-02
ES2221203T3 (es) 2004-12-16
HUP0003859A2 (hu) 2001-08-28
US6432993B1 (en) 2002-08-13
DE69824194D1 (de) 2004-07-01
PT1022272E (pt) 2004-08-31
AU740704B2 (en) 2001-11-15
CN1280570A (zh) 2001-01-17
PL200859B1 (pl) 2009-02-27
CA2305807A1 (en) 1999-04-15
RU2196141C2 (ru) 2003-01-10
BR9813848B1 (pt) 2011-07-12
WO1999018081A1 (fr) 1999-04-15
AU9458798A (en) 1999-04-27
BR9813848A (pt) 2000-10-03
KR20010030961A (ko) 2001-04-16
DE69824194T2 (de) 2005-01-13
CZ20001219A3 (cs) 2000-08-16
CN1255386C (zh) 2006-05-10
NO20001816L (no) 2000-06-07
HU228193B1 (en) 2013-01-28
ID23891A (id) 2000-05-25
HUP0003859A3 (en) 2005-09-28
TW475931B (en) 2002-02-11
MXPA00003546A (es) 2002-08-06
ATE267814T1 (de) 2004-06-15
NZ503794A (en) 2002-09-27
EP1022272A1 (en) 2000-07-26
CA2305807C (en) 2008-01-22
TR200000946T2 (tr) 2000-07-21
CZ302475B6 (cs) 2011-06-08
EP1022272A4 (en) 2002-07-17
HK1027354A1 (en) 2001-01-12

Similar Documents

Publication Publication Date Title
NO318070B1 (no) Substituerte, kondenserte heterosykliske forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene til fremstilling av medikamenter
US5166172A (en) Fumagillol derivatives and pharmaceutical compositions thereof
EP2404918B1 (en) Pyridine derivative as ppary inhibitor
US5164410A (en) Fumagillol derivatives and pharmaceutical compositions thereof
RU2456276C2 (ru) Бензимидазольные производные, фармацевтическая композиция на их основе и способы их применения
US5965589A (en) Thiazolidinedione derivatives, their production and use
US4803216A (en) Pyrazole-3-amines as anti-inflammatory agents
AU630196B2 (en) Heterocyclic substituted 4-amino phenol derivatives
KR20060134081A (ko) 피페리디닐알킬카르바메이트 유도체, 그의 제조 방법 및그의 ｆａａｈ 효소 억제제로서의 용도
EP2070913A1 (en) Ester derivatives as phosphodiesterase inhibitors
WO2000061581A1 (en) Amine derivatives
EP2152269A1 (en) Piperidine/piperazine derivatives
US5866571A (en) 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones
EP1834953A1 (en) Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
KR100204697B1 (ko) 트리아졸릴 치환된 3급 아민 화합물 또는 이의 염
US5646162A (en) Oxy-phenyl-(phenyl)glycinolamides with heterocyclic substituents
EP1914229B1 (en) Novel cercosporamide derivative
US4914099A (en) Hydantoin derivatives as aldose reductase inhibitors
JP4169450B2 (ja) インスリン抵抗性改善剤
US20070049621A1 (en) 6-Alkylamino-2-methyl-2'-(N-methyl substituted sulfonamido)methyl-2H-1-benzopyran derivative as anti-inflammatory inhibitor
US4088764A (en) Pharmaceutically active derivatives of 1-phenoxy-3-amino-propan-2-ol
CA2222687A1 (en) Novel naphthyridine derivatives
US4910313A (en) Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and process for the treatment of certain diseases in humans
WO2000061582A1 (fr) Derives imidazole condenses substitues
EP1317432B1 (en) Piperidine derivatives for use as 2,3-oxidosqualene-lanosterol cyclase inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees